文献速递妇科

奥拉帕利与尼拉帕利维持治疗在BRCA突变新诊断晚期卵巢癌中的生存结局比较

Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2023-12-16

这项多中心回顾性队列研究比较奥拉帕利与尼拉帕利维持治疗在BRCA突变新诊断晚期上皮性卵巢癌中的生存结局与不良事件。经3:1倾向性评分匹配后,奥拉帕利组80例与尼拉帕利组31例,中位无进展生存期未达到 vs 31.5个月(HR 1.08;95%CI 0.47-2.52;p=0.854),中位总生存期两组均未达到(HR 0.42;95%CI 0.01-17.61;p=0.649)。尼拉帕利组血小板减少(p=0.021)和中性粒细胞减少(p=0.011)发生率更高。

要点

  • 匹配队列中奥拉帕利组与尼拉帕利组中位无进展生存期未达到 vs 31.5个月,无显著差异。
  • 两组中位总生存期均未达到(HR 0.42;95%CI 0.01-17.61;p=0.649)。
  • 尼拉帕利组血小板减少(p=0.021)和中性粒细胞减少(p=0.011)发生率更高。

核心结论

  • BRCA1/2突变晚期上皮性卵巢癌患者中,奥拉帕利与尼拉帕利维持治疗的总生存期无显著差异,提示需根据不良事件特征个体化选择PARP抑制剂。

研究设计与样本

  • 多中心回顾性队列研究,纳入对铂类化疗有反应的BRCA1/2突变(胚系和/或体细胞)新诊断晚期上皮性卵巢癌III-IV期患者。
  • 采用3:1倾向性评分匹配,匹配变量为残留病灶大小和胚系变异存在情况;匹配后奥拉帕利组80例,尼拉帕利组31例。

主要发现

  • 匹配队列中位无进展生存期:奥拉帕利组未达到 vs 尼拉帕利组31.5个月(HR 1.08;95%CI 0.47-2.52;p=0.854)。
  • 中位至首次后续治疗时间:奥拉帕利组未达到 vs 尼拉帕利组31.8个月(HR 1.20;95%CI 0.51-2.81;p=0.682)。
  • 中位总生存期:奥拉帕利组与尼拉帕利组均未达到(HR 0.42;95%CI 0.01-17.61;p=0.649)。
  • 任何级别血液学或非血液学治疗中出现的不良事件发生率:尼拉帕利组血小板减少(p=0.021)和中性粒细胞减少(p=0.011)发生率更高。

临床怎么用

  • 作者认为,对于BRCA1/2突变晚期上皮性卵巢癌患者,选择PARP抑制剂时应考虑不良事件特征以制定个体化策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This multicenter retrospective cohort study aimed to compare survival outcomes and adverse events between maintenance therapy with two poly (ADP-ribose) polymerase (PARP) inhibitors, olaparib and niraparib, in patients with BRCA-mutated, newly diagnosed advanced epithelial ovarian cancer (EOC) who responded to platinum-based chemotherapy. METHODS: We enrolled stage III-IV EOC patients with germline and/or somatic BRCA1/2 mutations that had received maintenance therapy with olaparib or niraparib. A 3:1 propensity score matching was conducted using two variables: residual disease size and the presence of germline variants. The primary outcome was progression-free survival (PFS), and the secondary outcomes were time to first subsequent therapy (TFST), overall survival (OS), and treatment-emergent adverse events (TEAEs). RESULTS: In the propensity score-matched analysis, 80 patients who received olaparib and 31 patients who received niraparib were matched (3:1). In the propensity score-matched cohort, median PFS with olaparib vs. niraparib was not reached vs 31.5 months (HR, 1.08; 95% CI, 0.47-2.52; p = 0.854). The median TFST was not reached vs 31.8 months (HR, 1.20; 95% CI, 0.51-2.81; p = 0.682), and neither olaparib nor niraparib reached the median OS (HR, 0.42; 95% CI, 0.01-17.61; p = 0.649). In terms of the incidence rates of any-grade hematologic or non-hematologic TEAEs, higher rates of thrombocytopenia (p = 0.021) and neutropenia (p = 0.011) were observed in the niraparib group. CONCLUSION: Advanced EOC patients with BRCA1/2 mutations exhibited no significant difference in OS between olaparib and niraparib, indicating the need to consider individualized strategies for selecting PARP inhibitors based on adverse event profiles.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim JH, Kim SI, Park EY, et al. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2023. PMID: 38104527. doi:10.1016/j.ygyno.2023.11.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。